Richard P Tobin

6PUBLICATIONS
46CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 13, 2026
Decitabine reverses innate immune gene suppression in rare melanomas.

|Jun 27, 2025
Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update.

Jessica S W Borgers, Theresa M Medina, William A Robinson

|Mar 08, 2024
MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade.

Nabanita Mukherjee, Elizabeth Katsnelson, Tonya M Brunetti

|Jun 30, 2023
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.

William H Palmer, Laura Ann Leaton, Ana Campos Codo

|Nov 15, 2022
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.

Richard P Tobin, Dasha T Cogswell, Victoria M Cates

|Jan 14, 2022
Circulating CD8<sup>+</sup> mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patients.

Victoria M Vorwald, Dana M Davis, Robert J Van Gulick

Pageof 1

Frequent Collaborators

4 joint publications

Jessica Sw Borgers

3 joint publications

Martin D McCarter

2 joint publications

Kasey L Couts

2 joint publications

William A Robinson